July 31 (Reuters) - Resmed ( RMD ) beat Wall Street

estimates for fourth-quarter profit on Thursday, driven by

strong demand for its devices used to manage sleep apnea.

The company makes continuous positive airway pressure (CPAP)

machines, a non-invasive treatment of sleep apnea, a common

disorder in which patients have brief interruptions of breathing

during sleep.

Resmed's ( RMD ) fourth-quarter revenue rose 10% to $1.35 billion,

beating analysts' estimates of $1.33 billion, according to data

compiled by LSEG.

The company posted adjusted profit of $2.55 per share for

the quarter ended June 30, compared to estimates of $2.48 per

share.

Some analysts had expected the U.S. approval of Eli Lilly's ( LLY )

blockbuster drug Zepbound to treat sleep apnea would

reduce demand for the company's devices.

Resmed ( RMD ) has shrugged off those concerns, saying it expects

consumer wearables tracking sleep health and GLP-1 therapies

such as Zepbound will encourage more patients to use its

devices.